Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EPS (Weighted Average and Diluted): 2021-2025

Historic EPS (Weighted Average and Diluted) for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $2.66.

  • Krystal Biotech's EPS (Weighted Average and Diluted) rose 192.31% to $2.66 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.68, marking a year-over-year increase of 275.28%. This contributed to the annual value of $3 for FY2024, which is 669.23% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's EPS (Weighted Average and Diluted) is $2.66, which was up 106.20% from $1.29 recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's EPS (Weighted Average and Diluted) registered a high of $2.79 during Q3 2023, and its lowest value of -$1.99 during Q1 2022.
  • Its 3-year average for EPS (Weighted Average and Diluted) is $0.75, with a median of $0.91 in 2024.
  • As far as peak fluctuations go, Krystal Biotech's EPS (Weighted Average and Diluted) plummeted by 168.92% in 2022, and later surged by 3,900.00% in 2025.
  • Over the past 5 years, Krystal Biotech's EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.95 in 2021, then plummeted by 31.58% to -$1.25 in 2022, then spiked by 124.80% to $0.31 in 2023, then skyrocketed by 393.55% to $1.53 in 2024, then surged by 192.31% to $2.66 in 2025.
  • Its last three reported values are $2.66 in Q3 2025, $1.29 for Q2 2025, and $1.20 during Q1 2025.